Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma

被引:26
|
作者
Lipton, L
Fleischmann, C
Sieber, OA
Thomas, HJW
Hodgson, SV
Tomlinson, IPM
Houlston, RS
机构
[1] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England
[2] London Res Inst, Mol & Populat Genet Lab, Canc Res UK, London WC2A 3PX, England
[3] St Marks Hosp, Canc Res UK Colorectal Unit, Harrow HA1 3UJ, Middx, England
[4] Guys Hosp, Dept Clin Genet, London SE1 9RT, England
关键词
CHEK2; 1100deIC; colorectal; neoplasm;
D O I
10.1016/S0304-3835(03)00391-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aneuploidy is a characteristic of a subset of colorectal tumours. CHEK2 (also known as CHK2) is one of the cell cycle checkpoint genes coding for a family of proteins that sense damage in eukaryotic cells. Germline variation in CHEK2 has recently been shown to confer cancer susceptibility. Heterozygous mutations have been identified in patients with TP53-negative Li-Fraumeni syndrome. Furthermore, the CHEK2 1100delC variant carried by 1% of the population has been shown to act as a low penetrance allele for both breast and prostate cancers. To further our knowledge about the contribution of CHEK2 1100delC to cancer incidence we have analysed a series of 149 patients with multiple colorectal adenomas some of whom developed colorectal cancer. The CHEK2 1100delC allele was not over-represented in cases suggesting that this variant is not associated with an increased risk of colorectal disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 152
页数:4
相关论文
共 50 条
  • [1] Colorectal cancer risk associated with the CHEK2 1100delC variant
    Katona, Bryson W.
    Yang, Yu-Xiao
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 103 - 105
  • [2] The CHEK2 1100delC variant in Swedish colorectal cancer
    Djureinovic, Tatjana
    Lindblom, Annika
    Dalen, Johan
    Dedorson, Stefan
    Edler, David
    Hjern, Fredrik
    Holm, Jorn
    Lenander, Claes
    Lindforss, Ulrik
    Lundqvist, Nils
    Olivecrona, Hans
    Olsson, Louise
    Pahlman, Lars
    Rutegard, Jorgen
    Smedh, Kennet
    Tornqvist, Anders
    Eiberg, Hans
    Bisgaard, Marie Luise
    ANTICANCER RESEARCH, 2006, 26 (6C) : 4885 - 4888
  • [3] Colorectal cancer and the CHEK2 1100delC mutation
    de Jong, MM
    Nolte, IM
    Meerman, GJT
    van der Graaf, WTA
    Mulder, MJ
    van der Steege, G
    Bruinenberg, M
    Schaapveld, M
    Niessen, RC
    Berends, MJW
    Sijmons, RH
    Hofstra, RMW
    de Vries, EGE
    Kleibeuker, JH
    GENES CHROMOSOMES & CANCER, 2005, 43 (04): : 377 - 382
  • [4] Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility
    Xiang, He-ping
    Geng, Xiao-ping
    Ge, Wei-wei
    Li, He
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) : 2546 - 2551
  • [5] CHEK2*1100delC and risk of chronic lymphocytic leukemia
    Sellick, Gabrielle S.
    Sullivan, Kate
    Catovsky, Daniel
    Houlston, Richard S.
    LEUKEMIA & LYMPHOMA, 2006, 47 (12) : 2659 - 2660
  • [6] CHEK2* 1100delC Mutation and Risk of Prostate Cancer
    Hale, Victoria
    Weischer, Maren
    Park, Jong Y.
    PROSTATE CANCER, 2014, 2014
  • [7] CHEK2:1100delC mutation and elevated breast cancer risk
    Pereira, LHM
    Sigurdson, AJ
    Doody, MM
    Pineda, MA
    Alexander, BH
    Greene, MH
    Struewing, JP
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 256 - 256
  • [8] CHEK2*1100delC and male breast cancer risk in Israel
    Ohayon, T
    Gal, I
    Baruch, RG
    Szabo, C
    Friedman, E
    INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (03) : 479 - 480
  • [9] The CHEK2*1100delC mutation has no major contribution in oesophageal carcinogenesis
    L B Koppert
    M Schutte
    M Abbou
    H W Tilanus
    W N M Dinjens
    British Journal of Cancer, 2004, 90 : 888 - 891
  • [10] Increased risk of breast cancer associated with CHEK2*1100delC
    Weischer, Maren
    Bojesen, Stig Egil
    Tybjaerg-Hansen, Anne
    Axelsson, Christen Kirk
    Nordestgaard, Borge Gronne
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 57 - 63